Lytix Biopharma – Licensing partner Verrica Pharmaceuticals announces the pricing of a underwritten public offering, raising approximately USD 42 million upon completion

21 Nov 2024 15:40 CET

Oslo, November 21, 2024: Lytix Biopharma refers to the release made today by its
licensing partner Verrica Pharmaceuticals, announcing the pricing of a USD 42
million underwritten public offering.

The offering is expected to close on November 22, 2024, and the gross proceeds
from the offering are expected to be approximately USD 42.0 million. Verrica
also granted the underwriter an option for a period of 30 days to purchase up to
7,080,000 additional shares.

The full announcement can be read via this link:
https://verrica.com/press_release/verrica-announces-pricing-of-42-0-million-publ
ic-offering/

Further information is available through Verrica Pharmaceuticals’ website.

For any questions, please contact:
Gjest Breistein, CFO
gjest.breistein@lytixbiopharma.com
+47 952 60 512

About Lytix Biopharma
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with
a highly novel technology based on world leading research in host-defense
peptide-derived molecules. Lytix Biopharma’s lead product, LTX-315, is a
first-in-class oncolytic molecule representing a new principle to boost
anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that can work
in many different cancer indications and treatment settings, both as mono- and
combination therapy.

About Verrica Pharmaceuticals
Verrica is a dermatology therapeutics company developing medications for skin
diseases requiring medical interventions. Verrica’s product YCANTH® (VP-102)
(cantharidin), is the first and only commercially available treatment approved
by the FDA to treat adult and pediatric patients two years of age and older with
molluscum contagiosum, a highly contagious viral skin infection affecting
approximately 6 million people in the United States, primarily children. YCANTH®
(VP-102) is also in development to treat common warts and external genital
warts, two of the largest remaining unmet needs in medical dermatology. Verrica
is developing VP-103, its second cantharidin-based product candidate, for the
treatment of plantar warts. Verrica has also entered a worldwide license
agreement with Lytix Biopharma AS to develop and commercialize VP-315 (formerly
LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell
carcinoma and squamous cell carcinoma. For more information, visit
www.verrica.com.

More information:
Access the news on Oslo Bors NewsWeb site